Connect Biopharma Holdings Limited
- Jurisdiction
China - ISIN
US2075231017 (CNTB )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. Read full profile
Stock price
Fundamentals
- Net revenue
€22.38M - Gross margin
95.6% - EBIT
-€50.01M - EBIT margin
-223.4% - Net income
-€49.27M - Net margin
-220.1%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: September 13, 2022
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |